Testing effectiveness (Phase 2)Study completedNCT03147404
What this trial is testing
Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic (GEP) Neuroendocrine Carcinoma (NEC, WHO Grade 3) as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
Who this might be right for
Neuroendocrine Carcinoma, Grade 3
Samsung Medical Center 14